

Discontinuation of isolation for persons with COVID-19: Is 10 days really safe?

Authors: Alvina Clara Felix¹, Anderson V de Paula¹, Andreia Cristina Ribeiro, Francini Camila da Silva, Marta Inemami, Angela A Costa, Cibele Odete D Leal¹, Walter M Figueiredo, Claudio Sérgio Pannuti¹, Camila Malta Romano^{1,3 #}

1. Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

2. Serviço Especial de Saúde de Araraquara, Universidade de São Paulo, Araquara, SP, Brazil

3. Laboratório de Virologia (LIMHC52), Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

keywords: COVID-19; isolation; cell culture; infectiousness.

Corresponding author #. Camila M Romano. Av Dr Eneas de Carvalho Aguiar, 470
Institute of Tropical Medicine, Virology lab. Zipcode 05403-000, Sao Paulo SP, Brazil.
Phone: 5511-30618668. Email. cmromano@usp.br

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background. The detection of SARS-CoV-2 RNA by real-time polymerase chain reaction (PCR) in respiratory samples from COVID-19 patients is not a direct indication of the presence of viable viruses. The isolation of SARS-CoV-2 in cell culture system however, can acts as surrogate marker of infectiousness. Cell culture based studies performed mostly with hospitalized and moderate/severe COVID-19 claims that no replication competent virus is found after 9 days of the symptoms onset in respiratory samples. Therefore, it is now recommended 10 days isolation before patient discharge. **Methods.** We cell-cultured 29 SARS-COV-2 RT-PCR positive respiratory samples at the 10th day after the illness in Vero E6 cells. After two passages, cytopathic effect and cycle threshold (CT) lower than the obtained in the original sample were used to determine positivity. **Findings** .We found viable particles in (7/29) 24% of samples tested. The positivity in cell culture was strongly associated ($p < 0.0001$) to the low cycle thresholds in clinical samples ($Ct < 21$). **Conclusion.** This data adds important knowledge to the current protocols for de-isolation of patients with non-hospitalized mild COVID-19.

Introduction

In June 2020, the Center for Diseases Control (CDC) updated the information about the time of isolation for COVID-19 patients that would prevent transmission to a susceptible individual. For exposed persons with no SARS-COV-2 confirmation, 10 days quarantine would be sufficient to reduce the transmission risk to 1% [1]. For confirmed mild and moderate COVID-19, the isolation can be also discontinued after 10 days after symptoms onset considering resolution of fever for at least 24 hours. This period however, would be extended in case of severe COVID-19, in patients presenting immunological conditions or in case the patient still reports symptoms [1].

Criteria for discharge patients without a negative RT-PCR involve risks but some issues were taken into consideration for the new resolution; in particular, the amount of accessible laboratory supplies for molecular SARS-COV-2 tests as well trained and available lab technicians in some areas. Such demand makes the initial recommendation of two negative RT-PCR tests for discharging nearly impossible to be done, especially in regions with high number of cases.

The primary recommendation of 14 days isolation for COVID-19 was based on initial description that patients with moderate/severe disease could remain RT-PCR positive until day 12-14 [2,3]. More recent studies revealed that positivity at upper and lower respiratory tract can last longer than 14 days with highest peak at day 3-5 of illness, with consistent decline over time [4,5]. However, despite viral RNA detection by RT-PCR no replication-competent virus (RCV) has been recovered from samples collected after 8 [6] or 9 days of the onset [5,7].

The time of infectiousness appears to be related to the disease severity, since accumulated evidences point that asymptomatic individuals clear the virus faster than symptomatic ones

[8]. A few studies that successfully isolated SARS-COV-2 from respiratory samples also correlated the positivity in cell culture to RT-PCR cycle threshold (C_T) values on the original clinical samples [6, 9].

Given the isolation interruption at the 10th day after the illness onset is becoming widely adopted and the presence of viable particles at this time was little evaluated so far, we explored the presence of replicating-competent viruses (RCV) in RT-PCR positive nasopharyngeal (NP) samples from patients with mild COVID-19 at day 10th of the illness onset. We also analyzed the relationship of the viral load in the NP samples with the presence/absence of viable particles in cell culture.

Material and Methods

This study was part of an umbrella project developed in Araraquara, a medium size city from São Paulo State (Brazil) that broadly evaluated the household transmission of SARS-COV-2. The project was approved by the Ethical committee from the Medical School of the University of Sao Paulo (CAPPESQ # 4.235.245). For this particular study, 53 patients with confirmed mild COVID-19 were invited to participate providing nasopharyngeal (NP) samples at the day 10 of illness (D10). Real time PCR using the Altona RealStar® SARS-CoV-2 RT-PCR Kit 1.0 (Altona Diagnostics GmbH, Hamburg, Germany) was run in all samples to confirm the virus presence. The Altona Real Star detects SARS-COV-2 through probes for β -Coronaviruses (targeting gene E) and SARS-COV-2 specific (targeting gene S). For further estimates, we considered gene S since it is the specific for SARS-COV-2. Samples were stored at -80°C for a maximum of two weeks before being processed for cell culture experiments. Since RT-PCR results were obtained in <24h, we were able to submit some fresh samples to viral isolation (prior the storage at -80°C). From a subset of the positive ones, 0.2ml of the raw samples were put in Vero E6 cells for isolation. We cultured

Vero E6 in Dulbecco minimal essential medium (DMEM) supplemented with 10% of fetal bovine serum (FBS), reduced to 2% for the isolation experiments. Two consecutive passages were performed to assure that isolated viruses were replication competent. Positive viral cultures were defined through the observation of cytopathic effect (CPE) in the second passage and increased C_T values in the second passage in comparison to the first. Statistical analysis was performed with GraphPad Prism version 7.0. Between-group comparisons were performed using a Student t or Mann-Whitney test.

Results

Twenty-three of the 53 recruited patients were female (43%) and the median age was 39 years (range 17-60). Forty from the 53 patients were SARS-COV-2 positive at D10 (79%) with the median C_T in S gene of 25.7 (range 12-32). From these, 29 had sufficient well-preserved material and were submitted to viral isolation in Vero cell culture.

After two cell-passages, eight samples presented cytopathic effect and positive RT-PCR in Vero cells and 21 did not. However, only seven (24%) filled the criteria CPE plus lower C_t than the original sample in the second passage. Three of the 8 patients with visible CPE at D10 had NP sample also collected at D13, and the material was submitted to virus isolation. However, no RCV was recovered at this time (Table 1).

Regarding the symptoms, three of the seven patients with confirmed RCV presented some symptom at the D10, though all of them reported that the symptoms were milder than those experienced during the acute phase (i.e. headache, loss of smell and tiredness – data not shown). It is noted that two patients with viable particles reported no symptoms at all at D10 (Table 1), and two patients did not answer the question.

Among patients from whom no RPV was recovered (22 samples), 7 reported symptoms at D10, nine reported no symptom at this time and 6 did not answer the question.

When we looked at the viral load in NP samples, we found that positive samples at cultures presented significant lower C_T (20- IQR, 16.5- 21) in comparison to negative samples at culture (C_T 29 -IQR, 24-32.2), $p < 0.0001$ (Table 1 and Figure 1).

Discussion

The primary recommendation of 14 days isolation for COVID-19 patients was based on description that individuals with moderate/severe disease could remain RT-PCR positive until day 12-14 [2,3,8,10]. A comprehensive meta-analysis emphasizes the need of isolating the patient early, since the most infectious period is during the first week after symptoms onset. The authors also noticed that no viable particles were detected after nine days from the symptoms onset despite positive RT-PCR in the clinical samples [3]. Based on these evidences, the suggested time for discharge the COVID-19 patient from isolation was reduced to 10 days considering the impossibility to perform molecular tests and the absence of symptoms at the time. Unfortunately, only three studies carefully evaluated the positivity in cell culture along the days [5-7].

The number of studies using cell system to determine the presence of viable SARS-COV-2 particles in clinical samples is still exceedingly small. Among the reasons, there are the requirement of special laboratory facilities and availability of well-conserved samples. For diagnostic purposes, viral culture is also in disadvantage in comparison to RT-PCR, especially during an epidemic situation. Yet, the presence of infectious viruses in cultured cells is the surrogate marker of infectivity.

We report here that mild COVID-19 patients can still be contagious at D10 from the illness onset even in the absence of symptoms. Positivity in cell culture was also strongly associated to cycle thresholds lower than 21 in S gene at the NP samples.

As already observed by others [6], the presence of replication-competent virus was dependent on the viral load in the original sample. However, the authors associated the presence of RCV to both C_T and the time interval from disease onset, since no patient sampled after D8 presented viable viruses. In fact, our data agrees to the link between C_T values of the sample and SARS-COV-2 growth in cell culture but it confronts the current recommended approach of 10 days isolation of COVID-19 patients as a safe measure to prevent transmission. More important, we were able to recover viable viruses from two patients even after the resolution of symptoms, indicating that this parameter may be not reliable to determine who may or may not be discharged from isolation.

It has to be mentioned that NP sample from one COVID-19 patient presented no increase in viral load at the second passage in cell culture in comparison to the original NP sample (ID #86088), though CPE was observed. It is possible that only a few particles of the original sample were actually replication-competent and therefore, two passages were not sufficient to observe a significant increase in the viral load. Thus, we should be hesitant to state that this particular sample was actually infectious at D10. Limitations of this study include the limited volume of clinical sample that precluded the viral isolation of all positive samples in D10 and the absence of successive clinical samples that would allow us to determine how long the individuals were still infectious.

In summary, available data on SARS-COV-2 culture along the disease are scarce, but indicated so far that persons with mild or moderate COVID-19 remain infectious no longer than 9 days after the symptom onset. Here we present for the first time evidences that individuals with C_T values <21 in clinical samples at the 10th day present replication competent viruses at this time. It is crucial to have in mind that we are not fully aware about

the sensitivity of the viral culture to recover SARS-COV-2 viable particles, which means that negative viral cultures do not necessarily implies that no infectious particle is present at all. Further studies are needed to determine if viable viruses can occur, as well as in what proportion, between the 10th and 14th days after disease onset. Transmission control strategies focused solely on the presence/absence of symptoms and qualitative PCR results to determine isolation time may be not sufficient to prevent SARS-COV-2 transmission. This work has important implications on the public health and epidemiological surveillance focused on mitigate the SARS-COV-2 transmission chain.

Funding: This work was supported by São Paulo Research Foundation (FAPESP) [2019/03859-9]; and Brazilian National Research Council (CNPq), [402794/2020-6].

References

1. Center for Diseases Control and Prevention. Duration of Isolation and Precautions for Adults with COVID-19. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/end-home-isolation.html>. Assessed 10 January, 2021.
2. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ*, **2020**; 369m1443.
3. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV-1 and MERS-CoV viral load dynamics, duration of viral shedding and infectiousness: a living systematic review and meta-analysis. *Lancet Microbe*, **2021**; 2; e13-e22.
4. Young BE, Ong SWX, Kalimuddin S et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. *JAMA*, **2020**; 323: 1488-1494.
5. Wölfel R, Corman VM, Guggemos W et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*, **2020**; 581: 465-469
6. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. *Clin Infect Dis*, **2020**; 71:2663-2666.
7. The COVID-19 Investigation Team. Kujawski SA, Wong KK et al. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. *Nat Med*, **2020**; 26: 861–868.

8. Chen , Zhu B, Hong W, et al. Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19.

Int J Infect Dis. **2020**; 98: 252-260.

9. Basile K, McPhie K, Carter I, et al. Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19. Clin Infec Dis, 2020;ciaa1579

10. Kim ES, Chin BS, Kang CK, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. J Korean Med Sci, **2020**; 35: e142.

Table1. Information regarding the virus isolation of samples at the 10th day of illness.

ID	Sample C _T at D10	Viral isolation at D10	C _T in the cell culture	Presence of Symptoms	Viral isolation at D14
86057	28/27	Negative		Nd	
86059	13/12	Positive	12/10	No	
86077	21/20	Positive	13/12	No	
86079	30/29	Negative	-	Yes	
86080	31/30	Negative	-	No	
86087	34/36	Negative	-	No	
86088¶	22/21	Positive	25/24	Nd	Negative*
86089	32/31	Negative	-	No	
86091	32/31	Negative	-	Yes	
86109	28/27	Negative	-	Nd	
86113	21/20	Positive	12/11	Nd	Negative**
86128	20/19	Positive	11/10	Nd	Negative***
86129	26/25	Negative	-	Nd	
86195	20/19	Positive	10/9	Yes	
86196	22/21	Positive	9/8	Yes	
86224	30/29	Negative	-	Yes	
86236	28/27	Negative	-	Yes	
86237	28/28	Negative	-	Yes	
86239	28/28	Negative	-	Nd	
86263	28/28	Negative	-	Yes	
86364	34/34	Negative	-	Yes	
86614	32/31	Negative	-	Yes	
86705	28/27	Negative	-	Nd	
86708	27/26	Negative	-	No	
86748	25/24	Negative	-	Yes	
86750	34/32	Negative	-	Yes	
86812	33/30	Negative	-	No	
86815	21/19	Positive	11/10	Yes	
86816	25/23	Negative	-	No	

Note. The C_T values are presented for the gene E /gene S.

¶ - Samples submitted with CPE but Ct in cell culture higher than the original sample.

C_T of the NP samples at D14 were respectively: * 27/28; **28/27 and ***27/26

Figure 1. Plot of cycle threshold (C_T) of the clinical samples at Day 10 in regard to the presence of replication competent virus (RCV) or not (NRCV) in cell culture experiment. Significance was $p < 0.0001$.

